New guidance on the licensing of biosimilar products that reduces unnecessary clinical trials is expected to put the UK ahead of Europe and facilitate a boom in these essential life-saving medicines, creating greater patient access and saving the National Health Service (NHS) hundreds of millions of pounds. It could also make biosimilars available for a broader range of less common conditions. Mark Samuels, Chief Executive of the British Biosimilars Association (BBA), examines the impact of this regulatory first and what it means for the UK market.
INNOVATION AND regulation are not always natural bedfellows, especially when it comes to medicines. In most cases, this is entirely appropriate because patients need treatments that have been through appropriately stringent and robust regulatory processes, assuring peace of mind for us all. People’s health is not an arena for untested products or processes; or for those without rigorous clinical experience.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Can’t attend live? No worries – register to receive the recording post-event.
However, new guidance, which has recently been introduced by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), can undoubtedly be deemed innovative and an appropriately bold approach grounded in both science and real-world experience. Moreover, it looks set to transform the UK biosimilars market.
First though, for the uninitiated, a few words on the rise of biosimilars in the UK. Biological medicines, including biosimilars, are highly complex, protein-based molecules made or derived from living organisms, typically using recombinant DNA technology. They are used to treat long-term and complex conditions such as cancer and a range of autoimmune disorders (eg, rheumatoid arthritis, psoriasis, Crohn’s disease) and growth disorders.
People’s health is not an arena for untested products or processes; or for those without rigorous clinical experience”
Biosimilar medicines are treatments that have been developed to be clinically equivalent to an existing biological medicine. They are marketed following the expiry of the patent on the originator or reference biologic. Biosimilars are comparable to their reference product with no clinically meaningful differences in safety, efficacy, quality, structural characteristics and biological activity.
Biological medicines have dominated global lists of best-selling prescription drugs, with successful treatments for rheumatoid arthritis and autoimmune diseases having led the way. As we move forward, other disease areas, such as oncology, are increasingly coming to the fore in new biosimilar medicines.
Several years ago, the UK was struggling to keep pace with the adoption of biosimilar medicines; with insufficient clinical awareness contributing to a lower comparative uptake than other European countries. However, in a relatively short time, the UK has gone from lagging to leading, and collaboration has been an essential aspect of this turnaround.
In the past, some clinicians and patients had been more cautious about embracing biosimilars due to their relative lack of comparable clinical experience. However, knowledge and understanding have grown, particularly around switching patients from the originator to a biosimilar medicine. Furthermore, NHS England has done tremendous work in bringing together the full range of stakeholders – the National Institute for Health and Care Excellence (NICE), industry groups, patient groups and doctors and nurses – to explain why the health service should adopt biosimilar medicines routinely. Regulatory science and real-world evidence underpin this increasing use of biosimilars.
Over the next 15 years, over 30 biological products will lose their exclusivity across Europe. Currently, eight out of 10 of the most expensive drugs used by the NHS are biologics. Therefore, access to biosimilars, which can reduce the price by up to 50 percent in some therapy areas, means saving the taxpayer hundreds of millions of pounds every year. To give one example alone, adalimumab, which came off patent in 2018, is expected to deliver the NHS £300 million of savings by the end of this year.1
Following a consultation last year, the MHRA has launched new guidance, including streamlined development in most cases. Typically, 50 to 60 different analytical methods characterise, control, measure and compare a biosimilar medicine to the originator version. These methods provide a complete picture and a robust set of information from which to ensure safety.
The new MHRA guidance builds on 15 years of positive clinical experience in switching patients to biosimilar medicines and tracking patient outcomes through follow-up clinical studies. Confirmatory trials have not been shown to offer any additional insights; however, they do add significant and unnecessary delays in biosimilars becoming available to patients. These new guidelines are grounded in scientific experience. Ultimately, we believe this will make a positive contribution to accelerating regulatory approvals for biosimilar medicines, leading to faster access for more patients and savings for the NHS, while maintaining regulatory robustness.
Manufacturing experience has shown that confirmatory clinical trials have never identified any new information about a product. In practice, it transpires these trials have added no meaningful data to what pharmaceutical companies already know from their existing systematic and state‑of‑the-art comparability studies. It is this robust and rigorous data that provides regulatory confidence.
Over the next five to 10 years, at least 20 more biosimilars will be launched in the UK and potentially more now, thanks to the new MHRA guidance. One will be a biosimilar of Lucentis, a treatment for age-related macular degeneration, a leading cause of blindness that affects 600,000 people in the UK, which should save the NHS hundreds of millions of pounds. This saving will enable the NHS to treat more patients within its finite resources.
Biosimilar medicines drive competition and offer a greater choice of affordable biological treatments. In an environment where demand for expensive biological drugs will increase over the coming years, biosimilars can release funds and free up resources so that patients benefit from reinvestment in services and improved access to new or innovative therapies. In turn, pharmaceutical and biopharmaceutical manufacturers will be motivated to develop new and pioneering treatments for future generations. This guidance brings the UK in line with other nations in terms of regulatory freedom and is expected to facilitate an influx of biosimilars to the market over the next decade.
About the author
Mark Samuels is the Chief Executive of both the British Biosimilars Association (BBA) and its sister body, the British Generic Manufacturers Association (BGMA). Mark’s career has spanned diverse experience across the life sciences sector. He is a former executive at Roche and co-founded the Medicines Discovery Catapult Ltd. He was the founding Managing Director of the Government’s Office for Clinical Research Infrastructure – instrumental in managing the Department of Health’s £0.6 billion/ year investment in research centres across the NHS. Mark served for seven years on the Chief Medical Officer for England’s strategy board for health research and has worked with Number 10 to contribute to the Prime Minister’s Strategy for UK Life Sciences.
About the British Biosimilars Association
The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association. The members of the BBA ensure access to high quality, safe and effective biosimilar medicines for UK patients. As industry experts, we partner with patients’ representatives, healthcare professionals, regulators and payers to increase understanding and to drive a sustainable environment for the development, production and continuing optimised use of biosimilar medicines across the UK.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.